Lyra Therapeutics Inc (LYRA) — Capital Reinvestment Ratio

Latest as of June 2021: 0.18x

Lyra Therapeutics Inc (LYRA) has a Capital Reinvestment Ratio of 0.18x as of June 2021, meaning it reinvests 0% of its operating cash flow ($3.38 Million) in capital expenditures ($625.00K). See LYRA cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.18x

Capex / Operating Cash Flow

Operating Cash Flow

$3.38 Million

USD

Capital Expenditures

$625.00K

USD

Data as of

Jun 2021

Most recent filing

Annual Capital Reinvestment Ratio for Lyra Therapeutics Inc (None–None)

Year-by-year Capital Reinvestment Ratio for Lyra Therapeutics Inc from None to None. For live market cap and broader valuation context, see Lyra Therapeutics Inc market capitalisation.

Year	Reinvestment Ratio	Operating CF (USD)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow